Amylyx Pharmaceuticals (AMLX) stock in focus

Amylyx Pharmaceuticals (AMLX) has drawn investor attention after a period where the shares show a small loss over the past month, yet a gain over the past 3 months and year to date.

The recent 6.2% 1 day and 8.8% 7 day share price returns contrast with a 1.4% 30 day share price decline. At the same time, the 33.6% year to date share price return and very large 1 year total shareholder return suggest momentum has been rebuilding after earlier weakness, as reflected in the 54.6% 3 year total shareholder return loss.

If Amylyx’s move has you looking beyond a single biotech name, this is a good moment to scout 29 healthcare AI stocks as potential next candidates for your watchlist.

With Amylyx trading at US$15.26 and sitting at a 42% discount to the average analyst price target and a reported 77% intrinsic discount, you have to ask whether this is a genuine mispricing or the market is already factoring in future growth.

Price to book of 5x: Is it justified?

On the surface, Amylyx looks cheap compared to valuation models, yet its current valuation on a price to book basis tells a different story.

The P/B ratio compares the company’s market value to the book value of its net assets, and at 5x it sits above several benchmarks. For a clinical stage biotech with limited revenue and ongoing losses, a higher P/B often reflects investor expectations around the future value of the pipeline rather than current earnings power.

Here, Amylyx’s 5x P/B ratio is described as expensive both versus the broader US Pharmaceuticals industry average of 2.3x and relative to its peer group at 5x. That suggests the current share price is already assigning a full valuation to the balance sheet, even as our DCF work points to a fair value of $67.14 and the shares trade at $15.26. These mixed signals highlight how sensitive biotech valuations can be to assumptions about future cash flows and clinical outcomes, rather than to today’s accounting capital.

Result: Price to book of 5x (OVERVALUED)

However, you still face clear risks here, including ongoing net losses of US$149.282 million and the uncertainty that surrounds multiple early stage clinical trials.

Another view on value

The P/B work suggests Amylyx looks expensive at 5x, yet our DCF model points to a different conclusion. With a fair value estimate of $67.14 compared with a $15.26 share price, the DCF output indicates that the stock appears heavily undervalued. Which signal would you lean on here?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amylyx Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals seems balanced between risk and opportunity, take a moment now to review the numbers yourself and shape your own stance. You can start with 2 key rewards and 4 important warning signs.

Ready for more ideas worth your time?

If Amylyx has sharpened your thinking, do not stop here, your next strong idea could be one smart filter away in the Simply Wall Street Screener.

• Target potential mispricings by running through 54 high quality undervalued stocks that pair solid fundamentals with room for a re rating.
• Put resilience first and scan 80 resilient stocks with low risk scores designed to prioritise companies with steadier risk profiles.
• Hunt for your next under the radar opportunity with a screener containing 24 high quality undiscovered gems before everyone else starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.